Vical Incorporated (NASDAQ:VICL) traded down 1% during mid-day trading on Friday . The stock traded as low as $0.90 and last traded at $0.99. 12,057 shares traded hands during trading, a decline of 83% from the average session volume of 72,088 shares. The stock had previously closed at $1.00.
Several equities research analysts have recently issued reports on the stock. Zacks Investment Research raised shares of Vical from a “hold” rating to a “strong-buy” rating and set a $1.50 price objective for the company in a research report on Friday, November 2nd. HC Wainwright set a $4.00 price objective on shares of Vical and gave the stock a “buy” rating in a research report on Tuesday, October 30th.
The stock has a market cap of $24.33 million, a price-to-earnings ratio of -0.99 and a beta of 0.65.
Vical (NASDAQ:VICL) last released its earnings results on Monday, October 29th. The biotechnology company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.08. The business had revenue of $0.05 million during the quarter, compared to the consensus estimate of $0.18 million. Vical had a negative net margin of 300.44% and a negative return on equity of 31.61%. Equities research analysts predict that Vical Incorporated will post -0.85 EPS for the current year.
A number of institutional investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. grew its position in Vical by 47.5% in the third quarter. JPMorgan Chase & Co. now owns 138,960 shares of the biotechnology company’s stock valued at $190,000 after purchasing an additional 44,723 shares in the last quarter. BlackRock Inc. grew its position in Vical by 20.0% in the second quarter. BlackRock Inc. now owns 394,320 shares of the biotechnology company’s stock valued at $453,000 after purchasing an additional 65,732 shares in the last quarter. Renaissance Technologies LLC grew its position in Vical by 10.1% in the third quarter. Renaissance Technologies LLC now owns 966,549 shares of the biotechnology company’s stock valued at $1,324,000 after purchasing an additional 88,820 shares in the last quarter. Finally, Sio Capital Management LLC bought a new position in Vical in the third quarter valued at $1,699,000. 47.27% of the stock is owned by institutional investors and hedge funds.
About Vical (NASDAQ:VICL)
Vical Incorporated engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The company is developing VCL-HB01, an HSV-2 therapeutic vaccine that is in Phase II clinical trial to prevent and protect against lesion recurrence, as well as for the treatment of patients with symptomatic genital herpes infection; VL-2397 antifungal program, which is in Phase II clinical trial for the treatment of invasive fungal infections; and chronic hepatitis B that is in preclinical stage for the eradication of persistent HBV infection.
Recommended Story: What strategies should day traders use to execute a trade?
Receive News & Ratings for Vical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vical and related companies with MarketBeat.com's FREE daily email newsletter.